ostmenopausal osteoporosis is a leading cause of morbidity and mortality in the increasingly aging population, with fracture rates exceeding the combined incidence of breast cancer, stroke, and heart attacks in postmenopausal women (1) . Traditionally, this bone loss has been attributed solely to declining estrogen levels. However, we recently showed that the pituitary hormone folliclestimulating hormone (FSH), the secretion of which is under estrogenic feedback, directly enhances osteoclast formation and function. The deletion of its ␤-subunit (FSH␤) protects against bone loss despite severe hypogonadism (2) . This finding indicates that FSH is a requirement for hypogonadal bone loss and, although awaiting definitive proof, suggests strongly that elevated FSH contributes to the genesis of postmenopausal osteoporosis.
However, enhanced osteoclastogenesis, a consequence of the direct action of FSH on its G i -coupled receptor on osteoclast precursors, does not fully explain hypogonadal bone loss. There are accompanying alterations in bone and bone marrow, notably enhanced bone formation, increased T lymphocyte production, and macrophage activation. The alterations in immune function have been attributed to an increase in TNF␣ production that is thought to arise solely from estrogen deficiency. However, because TNF inhibits osteoblast differentiation in vitro, the increased bone formation has not been attributed to TNF␣. Thus, the genesis of enhanced bone formation, an essential component of the highturnover bone loss, has remained unclear.
Ablation of the TNF␣ gene in mice abrogates gonadectomyinduced bone loss, osteoclastic and osteoblastic activation, and the accompanying immune cell alterations (3) . That gonadectomy elevates FSH levels in these animals suggests that TNF␣ is essential for, and downstream of, FSH action on bone (3) . Consistent with this hypothesis, TNF␣ does not modulate FSH secretion (4) . In fact, there is direct evidence in Sertoli cells and testicular macrophages, respectively, that FSH enhances TNF receptor and TNF␣ expression (5, 6) . Together, these findings prompted us to explore whether FSH mediates the production of TNF␣ and whether the abrogation of bone loss in FSH␤-deficient mice arises in part from decreased TNF␣ production.
We show that FSH␤-deficient mice have low circulating TNF␣, that FSH directly stimulates TNF␣ production from bone marrow granulocytes and macrophages, and that TNF␣ stimulates osteoclast precursor expansion and osteoblast differentiation. We also find that ascorbic acid, which is required for posttranslational modification of proline to hydroxyproline in collagen and is thus used as a differentiation inducer in culture studies, acts to reverse the stimulatory effects of TNF␣ on osteoblast and osteoclast formation. Confirmatory evidence that high-turnover bone loss is due to enhanced osteoclast precursor expansion, and that TNF␣ is proosteoblastogenic rather than antiosteoblastogenic, comes from further mathematical modeling of the known action of TNF␣ in TNF␣-overexpressing mice. We propose that the effects of FSH on bone mass identified earlier (2) are, at least in part, exerted via the modulation of TNF␣ production by bone marrow macrophages and granulocytes.
Results

FSH Regulates TNF␣ Production.
Although estrogen is known to suppress TNF␣ production from immune cells (7), whether FSH or its lack thereof alters TNF␣ expression has never been investigated. We find that, despite severe estrogen deficiency, FSH␤-deficient mice have lower serum levels of TNF␣ compared with littermate controls (Fig. 1A) . This finding suggests that impaired FSH signaling attenuates the otherwise stimulatory effect of estrogen deficiency on TNF␣ production. In parallel experiments, the exposure of bone marrow cultures to recombinant FSH caused an increase in supernatant TNF␣ levels measured using an ELISA (Fig. 1B) .
Both macrophages, which together with granulocytes make up
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half of the cells present in bone marrow, and T lymphocytes, which account for 1-3% of cells in the bone marrow, have been suggested as sources of TNF␣ production in estrogen deficiency (8, 9) . To elucidate which cell(s) were producing TNF␣, we doubly stained cells from bone marrow with antibodies to TNF␣, as well as to markers for macrophages͞granulocytes (CD11b), B lymphocytes (B220), and T lymphocytes (CD3). We found that macrophages and granulocytes expressed high levels of TNF␣ after FSH stimulation but that other cell types did not ( Fig. 1 C-F) . These results suggest that TNF␣ up-regulation is likely downstream of FSH and is, at least in part, mediated by granulocytes and macrophages present in the bone marrow. (36) References are shown in parentheses.
TNF␣ Induces High-Turnover Bone Loss Through Osteoclast Precursor
Expansion. We next sought to understand how elevations in TNF␣ contribute to the observed high-turnover bone loss seen in hypogonadal states. Prior investigations suggest that there are three major actions of TNF␣ on bone. TNF␣ strongly augments osteoclast differentiation and resorptive function by stimulating the same signal transduction pathways induced by RANK-L (10). TNF␣ also increases the number of CD11b ϩ osteoclast precursors by enhancing macrophage colony-stimulating factor (M-CSF)-mediated proliferation (11, 12) . Additionally, TNF␣ potently inhibits osteoblast differentiation through negatively regulating the lifespan of osteoblast progenitors (13) . To determine which of these actions was critical in bringing about high-turnover bone loss, we adapted a mathematical model of bone metabolism to allow for the individual application of each of the three actions of TNF␣ (14) . Specifically, we examined how each of these actions contributed to the bone loss phenotype observed in animals overexpressing TNF␣ (Table 1 ; see also Table 2 , which is published as supporting information on the PNAS web site). Using this model, we found that simulating TNF␣-induced increases in the number of osteoclast precursors correctly accounted for most of the observed phenotype of TNF␣-transgenic mice ( Fig. 2A) . Furthermore, this model suggested that, if TNF␣ served solely to augment osteoclast differentiation, the number of osteoclast precursors would fall, not rise as was observed in vivo. Moreover, if TNF␣ inhibited osteoblast differentiation (as has been shown in vitro; see ref. 13 ), there would be concomitant declines in osteoclast numbers, not increases as noted in vivo. In agreement with the in silico finding that TNF␣'s main action is to augment osteoclast precursor numbers, TNF␣ added to osteoclast precursors 24 h before the addition of the differentiation-inducing cytokine RANK-L led to significantly greater increases in osteoclast formation than when TNF␣ and RANK-L were added simultaneously (Fig. 2B ).
Ascorbic Acid Reverses the Effects of TNF␣ on Osteoblasts and
Osteoclasts. Elevations in osteoblast function accompany the highturnover bone loss induced by estrogen deficiency. However, FSH does not impact osteoblast differentiation (2), and TNF␣ is an established potent inhibitor of osteoblast differentiation in vitro (15) . However, TNF␣-overexpressing transgenic mice have elevated osteoblast activity (Table 1 and 2 ). This incongruence prompted us to reexamine the function of TNF␣ on osteoblast differentiation. Although changes in osteoclast precursor numbers led to reactive increases in osteoblast numbers in our mathematical model, we attempted to isolate the function of TNF␣ on osteoblast differentiation by recreating the phenotype of the TNF␣-transgenic mouse treated with the RANK-L inhibitor osteoprotegrin (OPG), which blocks osteoclastogenesis. Interestingly, the bone mineral density of TNF␣-transgenics treated with OPG is higher than that of wild-type mice treated with OPG (Table 1 ). Attempts to reproduce that in vivo finding with our in silico model suggested that TNF␣ does not inhibit osteoblast differentiation; in contrast, they suggested that TNF␣ may increase osteoblast formation or decrease osteoblast apoptosis (Fig. 5 , which is published as supporting information on the PNAS web site).
Consistent with previous reports of TNF␣ action on osteoblast differentiation, we found that TNF␣ dose-dependently decreased the number of osteoblast-like colonies using the established protocol for CFU-F colony formation (Fig. 3B) . The established osteoblast differentiation method uses ascorbic acid (vitamin C) to induce the expression of osteoblast-specific genes. Although ascorbic acid is believed to boost the immune system, ironically recent findings suggest that it may inhibit inflammation. Specifically, the ascorbic acid derivative dehydroascorbic acid (DHA) noncompetitively inhibits IB kinases and thus prevents the activation of the downstream transcription factor NF-B (16). When NF-B activation is blocked, TNF␣ signaling leads to either apoptosis or replicative senescence (17, 18) . We hypothesized that ascorbic acid in the culture media might account for the inhibitory effects of TNF␣ on osteoblast differentiation. When we cultured total bone marrow without ascorbic acid, we found that TNF␣ dose-dependently increased the number of alkaline phosphatase-positive CFU-F colonies (Fig. 3A) .
More nonalkaline phosphatase-positive cells, such as macrophages, were observed in TNF␣-stimulated cultures without ascorbic acid compared with when it was added. We thus speculated that ascorbic acid might also inhibit TNF␣-induced macrophage differentiation. To test this hypothesis, we analyzed by flow cytometry the number of CD11b ϩ cells in total bone marrow cultures after the addition of increasing amounts of TNF␣. We found that TNF␣ application increased the number of CD11b ϩ cells but that the addition of ascorbic acid largely prevented this increase (Fig. 3C) . Likewise, the percentage of cells expressing the TNF␣-induced differentiation marker CD38 was attenuated by the inclusion of ascorbic acid (Fig. 3D) . Because CD11b ϩ cells serve as osteoclast precursors, we examined whether the loss of their expansion in the presence of ascorbic acid was able to prevent TNF␣-induced increases in osteoclast formation. We found that inclusion of ascorbic acid in the culture medium caused TNF␣ to inhibit osteoclast formation instead of stimulating it (Fig. 3 E and F) . Overall, we found that TNF␣ increases both osteoclast and osteoblast formation and that both of these actions are reversed by ascorbic acid. A comprehensive diagram showing the actions of FSH and TNF on the skeleton is shown in Fig. 4 .
Discussion
Severely estrogen-deficient FSH␤-null mice with normal testosterone levels (19) are resistant to bone loss that normally accompanies hypogonadism (2) . In contrast, mice deficient in the enzyme aromatase, which are equally severely hypogonadal, but with increased FSH and testosterone levels lose bone profoundly (19, 20) . Haploinsufficiency of FSH␤ increases bone mass but does not reduce estrogen or elevate testosterone (2, 19). The latter argues for Additionally, TNF␣ may prime macrophages to induce the proliferation of activated T lymphocytes, which highly express RANK-L and further contribute to TNF␣ production. The overabundance of osteoclast precursors, coupled with the osteoclastic differentiation agents FSH and RANK-L, which is expressed on T lymphocytes and stromal cells, likely compose the proosteoclastic component of high-turnover bone loss. TNF␣-induced increases in the number of osteoblasts, as well as resorption-induced osteoblast formation, likely compose the proosteoblastic component of high-turnover bone loss. TNF␣ action can be blocked by treatment with etanercept or analogs, or, as we have found in this report, through supplementation with ascorbic acid (vitamin C). The proosteoclastogenic actions of RANK-L can be blocked by RANK-Fc or OPG. The resorptive function of osteoclasts can be blocked by bisphosphonates, which are taken up by resorbing osteoclasts and modulate their sensitivity to apoptotic stimuli. Estrogen replacement therapy or selective estrogen receptor modulator (SERM) therapy, per our hypothesis, may decrease FSH levels to reduce TNF␣ expression. a direct, sex steroid-independent action of FSH on the skeleton. The premise that the osteoclast is the primary target for FSH is strengthened by our demonstration that FSH␤-null mice have suppressed osteoclast formation in vivo and in ex vivo cultures (2). This osteoclast-specific action noted in vivo is consistent with data showing a direct action of FSH in vitro on osteoclastogenesis and bone resorption in both mice and humans (2) .
A potential direct stimulatory action of FSH on bone mass in vivo, although awaiting definitive proof, is clinically meaningful in view of the close correlation between bone loss and changes in serum FSH, rather than sex steroids measured across the menopausal transition (21) . In another study, plasma levels of inhibin correlate with bone mass more strongly than with FSH (22) . The relationship between hormone levels and bone mass might simply be correlative rather than causal. However, the observation that amenorrheic women with high FSH levels are osteoporotic whereas amenorrheic women with normal or low FSH levels are not (23) highlights the potential importance of FSH in mediating, at least in part, hypogonadal bone loss in humans. Thus, a therapeutic goal could well be to suppress serum FSH levels, for example, with an antibody, in an effort to prevent bone loss, while sparing the ovaries. Genetic evidence in mice that an Ϸ50% reduction in plasma FSH enhances bone mass without affecting ovarian function (2) attests to the conceptual feasibility of this approach.
Although FSH stimulates bone resorption in vitro (2), this osteoclast-stimulatory action of FSH cannot fully explain the increased bone formation and immune cell alterations that accompany hypogonadal osteoporosis. There is strong evidence showing that T lymphocytes and inflammatory cytokines, such as TNF␣ and IL-7, play essential roles in hypogonadal bone loss (3, 24) . Evidence that FSH triggers TNF␣ production from macrophages and granulocytes, we believe, bridges the estrogen-FSH axis to the previously proven immune-mediated changes in bone cells (24) . Thus, we may have identified the physiological trigger, FSH, for the enhanced TNF␣ production that accompanies estrogen deficiency, which was not identified in previous studies (5), likely representing differences in experimental protocol.
That FSH stimulates TNF␣ production is complemented by loss-of-function studies demonstrating lowered TNF␣ levels in FSH␤-deficient mice, despite severe hypogonadism. Thus, although estrogen deficiency, for example after ovariectomy, elevates TNF␣ expression (24) , it appears from our study that FSH is required for this action, as it is for the accompanying bone loss (2) . Interestingly, mice deficient in the thyroid-stimulating hormone (TSH) receptor (TSHR) lose bone and have elevated TNF␣ levels; recombinant TSH expectedly inhibits TNF␣ expression (25) . Thus, the deletion of the TNF␣ gene on a TSHR-deficient background rescues the bone loss, suggesting that the osteopenia from TSHR deficiency arises mainly from elevated TNF␣ levels (25) (26) (27) . Taken together, the data indicate that (i) glycoprotein hormone receptors in bone regulate TNF␣ production and (ii) modulation of TNF may represent a key mechanism through which the pituitary gland affects bone mass.
Remaining unclear, however, is how TNF␣ causes high-turnover osteoporosis when in fact it suppresses osteoblast differentiation in vitro (13, 15) . By adopting a mathematical model, we found that all of the actions of TNF␣ in causing a high-turnover bone loss, for which the TNF␣-transgenic is a valid model, can be ascribed to an increase in the osteoclast precursor pool. Modeling the phenotype of TNF␣-transgenic mice treated with OPG suggested that TNF␣ was proosteoblastic. Consistent with this notion, there is a dissociation between the osteoclast and osteoblast phenotypes in TNF␣-Tg͞CD44 Ϫ/Ϫ mice (28) . Note, however, that FSH does not affect the osteoblast, although osteoblast precursors do express FSH receptors (2) . To understand the discrepancy between the modeling͞in vivo data and previously documented in vitro suppression of osteoblastogenesis, we determined whether ascorbic acid, an adjunct used in culture experiments, affected TNF␣-induced osteoblastogenesis. Indeed, we found that TNF␣ enhanced osteoblast differentiation in the absence of added ascorbic acid, whereas it inhibited osteoblastogenesis in cultures containing ascorbic acid. In fact, we also noted that the increase in the osteoclast precursor pool is reversed with ascorbic acid.
Prior studies have implicated ascorbic acid in the control of bone metabolism. Low dietary intake of ascorbic acid is associated with decreases in bone mass despite greater rates of bone formation and increases in mineralizing surfaces (29) . In postmenopausal women, a high intake of ascorbic acid lowers the levels of the bone turnover marker c-telopeptide (30) , whereas a low intake of ascorbic acid increases the rate of bone loss (31) . Our data provide a plausible explanation of these findings: decreased levels of ascorbic acid would elevate bone turnover causing increases in both osteoclastic and osteoblastic function, but with a net bone loss. Indeed, sfx mice deficient in an enzyme essential for the production of ascorbic acid undergo spontaneous fractures at an early age (32) . Thus, we speculate that the treatment of postmenopausal osteoporosis might benefit from supplementation with ascorbic acid. The Women's Health Initiative recently found, in a retrospective analysis, that women taking ascorbic acid in addition to estrogen had significantly greater bone mineral density gains at all sites compared with those on estrogen alone (33) . Further studies are urgently required to evaluate the beneficial effects of ascorbic acid in the treatment and prevention of hypogonadal bone loss in prospectively designed clinical trials.
Methods
Cell Preparation. Information regarding C57BL6J and FSH␤ mice is available elsewhere (2) . To obtain total bone marrow, mice were killed by an institutionally approved protocol, both femurs and tibiae were surgically extracted, and their bone marrow was flushed. The bone marrow pellet was resuspended in Opti-MEM I (Invitrogen, Carlsbad, CA) containing 5% FBS (Select USA stock; Invitrogen) and 1% penicillin͞streptomycin. CFU-F Colony Formation. Total bone marrow was diluted in ␣-MEM with 10% FBS and 1% penicillin͞streptomycin with or without 1 mM ascorbate-2-phosphate (phosphorylated form of ascorbic acid) and plated at 3 ϫ 10 6 cells per well in six-well plates. After 3 weeks (with ascorbate-2-phosphate) or 6 weeks (without ascorbate-2-phosphate) the cells were stained as described previously (28) .
Flow Cytometry. Total bone marrow was diluted in Opti-MEM (see Cell Preparation) and allowed to acclimatize in an incubator for 2 h. A 0-h sample was taken, FSH (100 ng͞ml) was added, and the cells were sampled at 1, 6, and 18 h after addition. The cells were fixed by using PhosphoFix (BD Biosciences,) and permeabilized by using 90% methanol at Ϫ20°C. Cells were stained for TNF␣-allophycocyanin alone or in combination with CD11b-Alexa Fluor 488, B220-phycoerythrin, or CD3-FITC (antibodies from BD Biosciences). Stained cells were washed, and 30,000 events were collected on a FACSCalibur as described previously (28) . FACS data were analyzed with Flow-Jo software (Tree Star, Ashland, OR) for Macintosh. Serum ELISAs. Serum from FSH␤-null mice and control littermates was taken as previously described (2) . A commercial kit for murine TNF␣ (KMC3011; Invitrogen) was used according to the manufacturer's directions. Serum was diluted 1:1 in diluent provided by the manufacturer. Four animals for each group were assayed two times; Student's paired t tests were performed from the sum of all measurements for each group.
Mathematical Modeling. The mathematical model of bone metabolism first reported by Lemaire et al. (14) was adapted such that the one-component osteoclast system was divided to include a preosteoclast component and an osteoclast component. All other parameters were set as previously described (14) . Calculations and graph plotting were carried out by using MatLab (Release 14; MathWorks, Natick, MA) with a three-file program consisting of separate files for parameters, model, and execution͞graphing.
